Fjarde Ap-fonden’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.2M | Buy |
66,985
+18,280
| +38% | +$5.51M | 0.1% | 196 |
|
|
2026
Q1 | $16.1M | Buy |
48,705
+18,490
| +61% | +$6.29M | 0.09% | 208 |
|
|
2025
Q4 | $12M | Hold |
30,215
| – | – | 0.1% | 185 |
|
|
2025
Q3 | $13.8M | Buy |
30,215
+200
| +0.7% | +$81.4K | 0.12% | 173 |
|
|
2025
Q2 | $9.79M | Buy |
30,015
+3,100
| +12% | +$858K | 0.09% | 214 |
|
|
2025
Q1 | $7.27M | Sell |
26,915
-2,200
| -8% | -$565K | 0.09% | 217 |
|
|
2024
Q4 | $6.85M | Buy |
29,115
+1,300
| +5% | +$342K | 0.07% | 266 |
|
|
2024
Q3 | $7.65M | Buy |
+27,815
| New | +$7.24M | 0.08% | 250 |
|
|
2024
Q1 | $4.1M | Sell |
27,415
-500
| -2% | -$83.4K | 0.05% | 394 |
|
|
2023
Q4 | $5.34M | Sell |
27,915
-500
| -2% | -$85.2K | 0.07% | 307 |
|
|
2023
Q3 | $5.03M | Sell |
28,415
-100
| -0.4% | -$19.1K | 0.07% | 309 |
|
|
2023
Q2 | $5.42M | Sell |
28,515
-1,400
| -5% | -$278K | 0.07% | 307 |
|
|
2023
Q1 | $5.99M | Buy |
29,915
+1,000
| +3% | +$210K | 0.08% | 269 |
|
|
2022
Q4 | $6.87M | Sell |
28,915
-1,800
| -6% | -$384K | 0.1% | 231 |
|
|
2022
Q3 | $4.48M | Hold |
30,715
| – | – | 0.06% | 357 |
|
|
2022
Q2 | $4.48M | Sell |
30,715
-5,900
| -16% | -$837K | 0.06% | 357 |
|
|
2022
Q1 | $5.98M | Sell |
36,615
-3,300
| -8% | -$503K | 0.06% | 346 |
|
|
2021
Q4 | $6.77M | Sell |
39,915
-969
| -2% | -$180K | 0.06% | 330 |
|
|
2021
Q3 | $7.72M | Sell |
40,884
-800
| -2% | -$150K | 0.07% | 281 |
|
|
2021
Q2 | $7.07M | Buy |
41,684
+1,000
| +2% | +$146K | 0.06% | 312 |
|
|
2021
Q1 | $5.74M | Buy |
40,684
+1,600
| +4% | +$241K | 0.05% | 366 |
|
|
2020
Q4 | $5.08M | Sell |
39,084
-2,300
| -6% | -$307K | 0.05% | 373 |
|
|
2020
Q3 | $6.03M | Buy |
41,384
+2,500
| +6% | +$355K | 0.07% | 284 |
|
|
2020
Q2 | $5.76M | Sell |
38,884
-1,300
| -3% | -$175K | 0.07% | 277 |
|
|
2020
Q1 | $4.37M | Buy |
40,184
+3,300
| +9% | +$381K | 0.07% | 274 |
|
|
2019
Q4 | $4.25M | Buy |
36,884
+5,900
| +19% | +$588K | 0.05% | 397 |
|
|
2019
Q3 | $2.49M | Buy |
30,984
+7,300
| +31% | +$578K | 0.03% | 492 |
|
|
2019
Q2 | $1.72M | Sell |
23,684
-5,100
| -18% | -$391K | 0.02% | 560 |
|
|
2019
Q1 | $2.69M | Buy |
28,784
+3,537
| +14% | +$296K | 0.03% | 490 |
|
|
2018
Q4 | $1.84M | Sell |
25,247
-3,400
| -12% | -$262K | 0.03% | 496 |
|
|
2018
Q3 | $2.51M | Sell |
28,647
-1,025
| -3% | -$103K | 0.04% | 522 |
|
|
2018
Q2 | $2.92M | Buy |
29,672
+1,487
| +5% | +$147K | 0.04% | 487 |
|
|
2018
Q1 | $3.36M | Sell |
28,185
-1,100
| -4% | -$142K | 0.05% | 417 |
|
|
2017
Q4 | $3.72M | Buy |
+29,285
| New | +$3.68M | 0.06% | 387 |
|
|
2016
Q4 | – | Sell |
-23,211
| Closed | -$1.57M | – | 627 |
|
|
2016
Q3 | $1.57M | Hold |
23,211
| – | – | 0.03% | 546 |
|
|
2016
Q2 | $1.29M | Sell |
23,211
-262
| -1% | -$16.5K | 0.03% | 572 |
|
|
2016
Q1 | $1.47M | Buy |
23,473
+1,892
| +9% | +$126K | 0.03% | 556 |
|
|
2015
Q4 | $2.03M | Buy |
21,581
+544
| +3% | +$50.4K | 0.05% | 433 |
|
|
2015
Q3 | $1.69M | Hold |
21,037
| – | – | 0.05% | 483 |
|
|
2015
Q2 | $2.52M | Buy |
+21,037
| New | +$2.51M | 0.06% | 377 |
|
Other funds holding ALNY
Fjarde Ap-fonden's ALNY Position: Q2 2026 in Review
Fjarde Ap-fonden increased its Alnylam Pharmaceuticals (ALNY) stake by 38% in Q2 2026, buying an estimated $5.51M and bringing the position to 66,985 shares worth $20.2M. The position accounts for 0.1% of the portfolio, ranked #196.
Fjarde Ap-fonden first reported a position in ALNY in Q2 2015 and has held it in 40 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Fjarde Ap-fonden held 66,985 shares of Alnylam Pharmaceuticals worth $20.2M as of Q2 2026.
- Fjarde Ap-fonden bought 18,280 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.51M.
- Alnylam Pharmaceuticals made up 0.1% of Fjarde Ap-fonden's portfolio in Q2 2026, its #196 holding.
- Fjarde Ap-fonden first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
- 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.